New Paper Highlights Evox Therapeutics’ Cutting-Edge Exosome Engineering Approach for Enhanced Surface Display of Biologics

On October 7, 2021, Evox Therapeutics Ltd., a leading exosome therapeutics company, announced that, in close collaboration with the lab of one of its co-founders at the Karolinska Institute, it has published an important paper in Nature Biomedical Engineering outlining the engineering of exosomes for surface display of proteins. The publication demonstrates the ability to engineer exosomes to display specific protein receptors on their surface and through that optimization achieve better efficacy relative to conventional biologics in three different mouse inflammatory disease models. In addition, Evox’s technology for displaying and oligomerizing proteins on the exosome surface significantly (p < 0.0001) outperforms other previously described exosome surface-display scaffolds including Lamp2b and PTGFRN. The article was published online on October 6, 2021 and is titled “Amelioration of Systemic Inflammation Via the Display of Two Different Decoy Protein Receptors on Extracellular Vesicles.”
Login Or Register To Read Full Story